Therapeutics

Each new modality needs to find its platform-disease fit—the diseases it is uniquely suited for. But finding fit has increasingly turned into a fight; many have crowded into the same indications. With an expanding arsenal to treat disease, how will patients, clinicians, and the market determine what tool to use?

Olga Troyanskaya, PhD, a professor in the department of computer science at Princeton and Deputy Director for Genomics at the Flatiron Institute's Center for Computational Biology, joins Vijay Pande, founding partner of a16z Bio + Health.

Carl June, MD, an immunologist and oncologist at the University of Pennsylvania, joins Jorge Conde, general partner at a16z Bio + Health.Carl June, MD, an immunologist and oncologist at the University of Pennsylvania, joins Jorge Conde, general partner at a16z Bio + Health.

In this episode, Dan joins general partner Jorge Conde and investment partner Becky Pferdehirt to discuss how he got started working in chemical biology and chemoproteomics and his experience founding companies, along with leading lab and pharma collaborations.

Today’s episode is with Greg Meyers, EVP and Chief Digital and Technology Officer at Bristol Myers Squibb (or BMS). He is joined by a16z Bio + Health general partner Jorge Conde.

a16z Bio + Health investment partner Becky Pferdehirt chats with Robbie Majzner, MD, an Assistant Professor of Pediatrics in the Division of Hematology and Oncology at Stanford, and co-founder of Link Cell Therapies.

Ben Cravatt, Professor in the Department of Chemistry at the Scripps Research Institute, and Gene Yeo, Professor of Cellular and Molecular Medicine at UCSD, join Vineeta Agarwala, general partner at a16z Bio + Health, and Bryan Faust, investing partner, to talk about their latest published research.

In this episode, Jorge Conde, general partner at a16z Bio + Health, talks with Josh Mandel-Brehm, founding CEO of CAMP4.

Kevin Parker, cofounder and CEO of Cartography Biosciences, joins Jorge Conde, general partner at a16z Bio + Health, and Olivia Webb, editorial lead.

The RNA technology underlying both the Moderna and Pfizer/BioNTech vaccines could give us our fastest ticket out of the COVID-19 pandemic. With their rapid development and the early signs of success, RNA-based therapeuti...

The entire healthcare system is built around the idea that we can detect, diagnose, and manage disease effectively for patients. This pandemic has been a stress test of that capability, and we have roundly failed that te...

There’s been a lot of talk lately about possibilities for treating aging—from blood transfusions from old mice to young, to eradicating “zombie” cells, to taking daily rapamycin and metformin pills to extend your healths...

The FDA just approved the first ever videogame that can now be legally marketed and prescribed as a medicine. It's a game called EndeavorRX (formerly known as Project EVO and developed by Akili Interactive based on technology licensed from a neuroscience lab at the University of California San Francisco) -- and is for 8-12 year olds with Attention Deficit Hyperactivity Disorder or ADHD. So where does this fit in the broader category of "digital therapeutics"? We debate and discuss all this in this week's episode of 16 Minutes on the News, with a16z partners Vijay Pande and Justin Larkin (former physician and entrepreneur who was most recently at Google Verily) and external guest Nikhil Krishnan (who covered digital health as an analyst at CB Insights, and now publishes the industry newsletter Out of Pocket).

a16z Journal Club covers recent advances from the scientific literature; this inaugural episode for bio covers 2 two different topics: (1) identifying new antibiotics through a novel machine-learning based approach; and (2) characterizing the novel coronavirus causing the COVID-19 pandemic.

1/ RCTs vs RWE’s has become a heated debate. Some believe that RWE would be cheaper and better, as there’s more data. Others believe that RCTs are the only statistically validated means to test a drug. Who’s right?

Editor's note: This is a list of selected resources on the novel coronavirus (formerly known as as 2019 n-CoV, now known as SARS-CoV-2) that causes COVID-19 disease. The list spans everything from official sources, track...

We are at the beginning of a new era for how we treat one of humankind’s oldest and worst foes—cancer. In this talk, given at the annual a16z Summit, Jonathan Lim, CEO and cofounder of Erasca, shows us where we are in ca...

Genetic engineering is in some sense as old as human history, when we first began selectively breeding livestock and crops. Then came the advent of biotech, and our ability to read, copy, edit, and now write DNA directly...

Novartis recently announced what is now the most expensive medicine in history: Zolgensma, a newly-approved gene therapy to treat a devastating disease called Somatic Muscular Atrophy, or SMA, will have a price tag of $2...

watch time: 16 minutes